Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo (NASDAQ: MASI) announced the CE marking and launch of its innovative rainbow® SuperSensor™ in Europe, designed for single-patient use. This advanced sensor can monitor 12 physiological parameters noninvasively, including SpO2, total hemoglobin, and respiration rate. The SuperSensor enhances continuous monitoring capabilities, allowing clinicians to assess patients' conditions more accurately. With proven effectiveness in improving patient outcomes, this technology aims to bolster patient safety and streamline care in critical settings.
Masimo (NASDAQ: MASI) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET. A live webcast will be available on the company's website, with a replay following the event. Masimo is a leader in medical technology, known for its innovative monitoring solutions including Masimo SET® pulse oximetry, which has been validated in over 100 studies. The technology aims to enhance patient outcomes and minimize healthcare costs, with significant usage across major hospitals.
Masimo (NASDAQ: MASI) announced a study revealing that the Oxygen Reserve Index (ORi) may provide early warnings for hypoxemia during endotracheal intubation (ETI) in ICU patients. Conducted by researchers at Centre Hospitalier Universitaire in France, the study showed a median of 81 seconds between ORi decrease and oxygen saturation drop, allowing for preventive actions. The study concluded that a higher ORi during preoxygenation is independently protective against hypoxemia. However, ORi lacks FDA clearance in the U.S.
Masimo (NASDAQ: MASI) has announced its commitment to raising awareness about opioid overdose risks on International Overdose Awareness Day (August 31). The initiative is in response to alarming statistics, with opioid-related deaths in England and Wales reaching their highest levels since 1993. The company is launching an educational website, www.OpioidSafety.org, to provide crucial information on the dangers of opioid use, even when prescribed. Collaborating with the Penington Institute, Masimo will fund research on opioid overdoses, with the first report expected in 2022.
Masimo (NASDAQ: MASI) has launched the Masimo SafetyNet Alert in Western Europe, an advanced blood oxygen monitoring system designed for home use, particularly for patients taking opioids. This system utilizes innovative Signal Extraction Technology to monitor blood oxygen saturation (SpO2) and pulse rate. It can alert users and emergency contacts in case of dangerous drops in oxygen levels, potentially preventing fatal overdoses. Masimo SafetyNet Alert aims to improve patient safety and reduce opioid-related deaths.
Masimo (NASDAQ: MASI) highlights the findings from a recent whitepaper by the Society for the Advancement of Patient Blood Management (SABM), advocating for continuous hemoglobin (Hgb) monitoring to enhance patient care in critical settings. The whitepaper cites more than a decade of research and emphasizes that real-time Hgb data aids clinicians in making timely decisions, ultimately improving outcomes, reducing blood transfusions, and decreasing costs. Continuous monitoring can lead to significant reductions in post-surgery mortality rates across multiple countries.
Masimo (NASDAQ: MASI) published a study in the Turkish Journal of Emergency Medicine, highlighting the correlation between the Pleth Variability Index (PVi) and volume changes in hemodialysis patients. Conducted by researchers at Kecioren Training and Research Hospital, the study involved 60 patients and demonstrated that PVi increased significantly after fluid removal, indicating its potential for monitoring volume status in critically ill patients. While PVi shows promise, its accuracy in predicting fluid responsiveness can be variable and should not solely drive fluid management decisions.
Masimo (NASDAQ: MASI) announced findings from a study published in the Journal of Pain & Relief, showing that its product Masimo Bridge® significantly reduces postoperative opioid requirements and pain in kidney donor surgery patients. Conducted by researchers at the University of Pittsburgh, the study found a 75.4% reduction in opioid use and 58.3% reduction in pain levels at 24 hours post-surgery for patients using Bridge. The researchers highlighted the potential of this non-invasive device to help combat opioid dependence amid an ongoing opioid crisis.
Masimo reported its Q2 2021 financial results, with product revenue rising 1.4% to $305.1 million. However, the constant currency basis showed a slight decline of 0.1%. The GAAP operating margin improved to 21.3%, while non-GAAP operating margin increased to 23.4%. Net income stood at $50.2 million or $0.88 per diluted share, compared to $55.8 million or $0.96 in Q2 2020. For 2021, the company updated its full-year revenue guidance to $1.216 billion, reflecting a 6.3% growth.
Masimo (NASDAQ: MASI) is set to release its second quarter 2021 financial results on July 27, 2021, after market close. The results will be discussed in a conference call at 1:30 p.m. PT, led by CEO Joe Kiani and CFO Micah Young. Participants can register for the call via a provided link to receive dial-in details. Masimo specializes in medical technology, focusing on innovative monitoring solutions that improve patient outcomes. Its Masimo SET® technology has been validated in over 100 studies, showcasing its effectiveness in clinical settings.